Abnormalities of the endosomal-lysosomal system occur in Alzheimer's disease (AD). Relatively little is known about multivesicular endosomes and their contributions to AD pathogenesis and maintenance of neuronal homeostasis, including exosome biogenesis and function. Our preliminary findings suggest that endosomal-lysosomal system dysfunction in AD, which prevents efficient transport and degradation of substrates, can be compensated for by enhanced secretion of exosomes containing neuroprotective factors along with toxic proteins.
In Aim 1 we will determine whether endosomal dysfunction (examined in Projects 1 and 4) and autophagic dysfunction (Project 2) affect exosome generation and secretion in mouse disease models.
In Aim 2, using in vivo and in vitro models, we will study the effects of enhancing or inhibiting lysosomal system function on exosome secretion and the reciprocal effects of enhancing or inhibiting exosome generation on AD-related lysosomal pathology. We demonstrated that cystatin C (CysC) can induce beneficial autophagic and lysosomal degradation and can also enhance exosomal secretion, resulting in neuroprotection. Both extracellular soluble human CysC and exogenous exosomes containing CysC protect cells from death. We propose that CysC can regulate whether proteins are directed to autophagic vesicles for lysosomal degradation or for release into the extracellular space via exosomes, and that both pathways potentially rescue deleterious effects of AD-related dysfunctions of the lysosomal system.
In Aim 3 we will test this hypothesis, demonstrating that reduced CysC levels, which are associated with AD, deprive cells of the protection provided by both soluble CysC and CysC-loaded exosomes. We will further determine whether therapeutic strategies that restore or enhance CysC activity will attenuate AD pathologies. Exosomal membrane-encased proteins are more stable than soluble proteins in the extracellular environment, offering long-lived and potentially spatially distant neuroprotective effects. Thus, exosomes released from cells in the central nervous system may have important protective functions, and CysC-loaded exosomes are a potential therapeutic strategy for the treatment of AD and other neurodegenerative disorders.
Mechanisms to eliminate toxic material are essential for cellular survival and fail In Alzheimer's disease. We will study how enhancing the secretion of exosomes, a recently identified vesicular pathway for releasing toxic material from the cell, might alleviate brain abnormalities and whether exosomes loaded with the protective protein cystatin C represent a novel therapeutic strategy for the treatment of neurodegenerative disorders.
|Li, Wei; Sultana, Nargis; Siraj, Nabeel et al. (2016) Autophagy dysfunction and regulatory cystatin C in macrophage death of atherosclerosis. J Cell Mol Med 20:1664-72|
|Mathews, Paul M; Levy, Efrat (2016) Cystatin C in aging and in Alzheimer's disease. Ageing Res Rev 32:38-50|
|Rosa, Elyse; Mahendram, Sujeivan; Ke, Yazi D et al. (2016) Tau downregulates BDNF expression in animal and cellular models of Alzheimer's disease. Neurobiol Aging 48:135-142|
|Colacurcio, Daniel J; Nixon, Ralph A (2016) Disorders of lysosomal acidification-The emerging role of v-ATPase in aging and neurodegenerative disease. Ageing Res Rev 32:75-88|
|Strupp, Barbara J; Powers, Brian E; Velazquez, Ramon et al. (2016) Maternal Choline Supplementation: A Potential Prenatal Treatment for Down Syndrome and Alzheimer's Disease. Curr Alzheimer Res 13:97-106|
|Rao, Mala V; Campbell, Jabbar; Palaniappan, Arti et al. (2016) Calpastatin inhibits motor neuron death and increases survival of hSOD1(G93A) mice. J Neurochem 137:253-65|
|Tiernan, Chelsea T; Ginsberg, Stephen D; Guillozet-Bongaarts, Angela L et al. (2016) Protein homeostasis gene dysregulation in pretangle-bearing nucleus basalis neurons during the progression of Alzheimer's disease. Neurobiol Aging 42:80-90|
|Kim, S; Sato, Y; Mohan, P S et al. (2016) Evidence that the rab5 effector APPL1 mediates APP-Î²CTF-induced dysfunction of endosomes in Down syndrome and Alzheimer's disease. Mol Psychiatry 21:707-16|
|Jiang, Ying; Rigoglioso, Andrew; Peterhoff, Corrinne M et al. (2016) Partial BACE1 reduction in a Down syndrome mouse model blocks Alzheimer-related endosomal anomalies and cholinergic neurodegeneration: role of APP-CTF. Neurobiol Aging 39:90-8|
|Morales-Corraliza, Jose; Wong, Harrison; Mazzella, Matthew J et al. (2016) Brain-Wide Insulin Resistance, Tau Phosphorylation Changes, and Hippocampal Neprilysin and Amyloid-Î² Alterations in a Monkey Model of Type 1 Diabetes. J Neurosci 36:4248-58|
Showing the most recent 10 out of 141 publications